Coronary Artery DiseaseComparative Effectiveness of Ranolazine Versus Traditional Therapies in Chronic Stable Angina Pectoris and Concomitant Diabetes Mellitus and Impact on Health Care Resource Utilization and Cardiac Interventions
Section snippets
Methods
To compare differences between ranolazine and traditional AA therapies, we conducted a retrospective, quasi-experimental between-group analysis using propensity matching. The data source was the Clinformatics Data Mart representing a commercially available data source for research purposes from United Healthcare's nationwide patient population. The patient population included United Healthcare's fully insured, Medicaid, and Medicare Advantage population representing 49 million unique subjects.
Results
From January 1, 2008, through December 31, 2012, of those meeting the inclusion criteria, 8,008 were identified with CSA receiving either a BB (n = 2,002), CCB (n = 2,002), LAN (n = 2,002), or ranolazine (n = 2,002; Figure 2). As seen in Table 1, baseline characteristics were well matched between groups. Most patients were men, had a mean age of 66 years, and resided within the Southern United States. The type of medical coverage varied between therapeutic treatment groups. For private and
Discussion
As CSA is closely tied to coronary artery disease (CAD) and its complications, this particular CV condition has been associated with a large increase in health care resource utilization. In a post hoc analysis of the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-Elevation ACS–Thrombolysis in Myocardial Infarction 36 trial, Arnold et al7 found that compared to those without angina, patients with daily angina after an ACS event had a 2-fold increase in health care resource
Disclosures
Drs. Hartsfield and Koch are employed by Gilead Sciences. None of the other authors have conflicts of interest to disclose.
References (21)
- et al.
2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons
J Am Coll Cardiol
(2012) - et al.
Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (type 2 diabetes evaluation of ranolazine in subjects with chronic stable angina)
J Am Coll Cardiol
(2013) - et al.
Beta-blocker therapy and cardiac events among newly diagnosed coronary heart disease
J Am Coll Cardiol
(2014) - et al.
Costs and clinical outcomes associated with use of ranolazine for treatment of angina
Clin Ther
(2012) - et al.
Impact of ranolazine on clinical outcomes and healthcare resource utilization in patients with refractory angina pectoris
Am J Cardiovasc Drugs
(2013) - et al.
Heart disease and stroke statistics--2015 update: a report from the American Heart Association
Circulation
(2015) - Healthcare Costs and Utilization Project. Chronic condition indicator for ICD-9-cm. Available at:...
- et al.
Measuring concurrent adherence to multiple related medications
Am J Manag Care
(2009) - et al.
Economic impact of angina after an acute coronary syndrome: insights from the MERLIN-TIMI 36 trial
Circ Cardiovasc Qual Outcomes
(2009) - et al.
Effects of ranolazine on exercise tolerance and hba1c in patients with chronic angina and diabetes
Eur Heart J
(2006)
Cited by (0)
Funding: The present study was supported by a grant from Gilead Sciences, Foster City, California.
See page 1327 for disclosure information.